What is it about?
Antibody-based immunotherapy targeting amyloid-β (Aβ) is a promising approach for Alzheimer’s disease (AD). However, its efficacy is limited by rapid hepatic sequestration, complement activation, and liver dysfunction. In this study, we synthesized low-immunogenic 450-nm functionalized mesoporous silica nanoparticles (PEG-MSN-1F12) by conjugating the anti-Aβ42 monoclonal antibody 1F12 to polyethylene glycol-modified mesoporous silica nanoparticles to address these challenges. In APP/PS1 mice, intravenous PEG-MSN-1F12 administration markedly enhanced peripheral Aβ clearance, promoted intestinal excretion, reshaped gut microbiota, and alleviated intestinal inflammation, thus reducing AD-associated hepatic burden.
Featured Image
Photo by Robina Weermeijer on Unsplash
Why is it important?
The clinical efficacy of anti–amyloid-β (Aβ) immunotherapy is constrained by rapid hepatic sequestration, immune-related adverse events, and limited long-term safety, particularly among patients with impaired hepatic function. We demonstrate that size-engineered antibody–nanoparticle conjugates can bypass hepatic sequestration and promote intestinal Aβ elimination, markedly reducing complement activation and systemic inflammation. This peripheral detoxification strategy lowers brain amyloid burden and improves cognition without increasing immunogenicity. By identifying a clinically actionable route for improving antibody pharmacokinetics and safety, our findings provide a translational framework for developing safer and more effective immunotherapy strategies for Alzheimer’s disease and other chronic neurodegenerative disorders
Perspectives
This study demonstrates that dimensionally engineered antibody-nanoparticle conjugates can circumvent hepatic sequestration and promote intestinal Aβ clearance, thereby significantly reducing complement activation and systemic inflammatory responses. This peripheral detoxification strategy alleviates cerebral amyloid burden and improves cognitive function without increasing immunogenicity. The study provides a framework for translational research into immunotherapeutic strategies for Alzheimer's disease and other chronic neurodegenerative disorders.
Haiming Luo
Hainan University
Read the Original
This page is a summary of: Size-tailored nanoparticle–antibody conjugates overcome hepatic sequestration in Alzheimer’s disease treatment, Proceedings of the National Academy of Sciences, September 2026, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2603034123.
You can read the full text:
Contributors
The following have contributed to this page
